Sentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)


You May Also Like

Novan Announces Management Changes and Provides Business Update

Paula Brown Stafford promoted to President and newly created role of Chief Operating Officer ...

Annual Report 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report ...